Project Grant K99CA304503
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$156K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This Project Grant award, with a total funding of $138,742, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The primary awardee, The Johns Hopkins University, will utilize single-cell RNA sequencing data to develop statistical methods for identifying cellular interactions that are altered by combination immunotherapy treatments in pancreatic ductal adenocarcinoma (PDAC). Additionally, the award will support experiments...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $618,928.00 in funding to The Regents of the University of California, Berkeley to conduct research aimed at understanding the mechanisms by which regulatory T cells (Tregs) suppress antitumor immune responses within the tumor microenvironment and tumor-draining lymph nodes. The key goals are to decipher whether blocking Treg function in tumors is sufficient for tumor control, and to...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.396 - Cancer Biology Research provides $552,874 in funding to The Regents of the University of California, San Francisco (UCSF) from August 1, 2024 to July 31, 2029. The project aims to dissect the cellular and molecular pathways by which the A20 protein regulates anti-tumor immunity. Specifically, the research will focus on understanding how A20, a potent regulator of immune homeostasis, restrains both acute and anamnestic...
This federal Project Grant award of $269,280 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The research aims to evaluate whether depletion of senescent and pro-fibrotic cells in the PDAC tumor microenvironment can improve the efficacy of standard-of-care...
This Project Grant award, titled "A NOVEL IMMUNOTHERAPY FOR PANCREATIC CANCER USING MICRO-RNA-29A," was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to the University of Miami in the amount of $107,948. The award will support research to determine the contribution of the TNFR2-miR-29a axis to CD8 T cell dysfunction in pancreatic ductal adenocarcinoma (PDAC), with the goal of generating durable T-cell mediated anti-tumor activity. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to The University of Texas MD Anderson Cancer Center to conduct research on the functional contribution of extracellular vesicles in pancreatic cancer. The research aims to investigate how cancer cell-derived extracellular vesicles modulate the tumor microenvironment to facilitate pancreatic cancer initiation, progression, and metastasis. The goal is to identify novel...
This $1,130,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed anti-Tn (AREMAB6) monoclonal antibody. The key objectives are to: 1) determine how the Tn antigen enhances PDAC progression and identify Tn-expressing glycoproteins; 2) validate the role of natural killer cells in AREMAB6-mediated...